Welcome to the e-CCO Library!

P492: Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for ulcerative colitis: A Phase 3, randomized, placebo-controlled study: Results of the LIBERTY-UC study
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Sands, B.E.(1)*;Hanauer, S.B.(2);Colombel, J.F.(3);Sandborn, W.(4);Schreiber, S.(5);Danese, S.(6);Klopocka, M.(7);Kulynych, R.(8);Kierkus, J.(9);Soltysiak, A.(10);Smolinski, P.(11);Gonciarz, M.(12);Sreckovic, S.(13);Valuyskikh, E.(14);Horynski, M.(15);Gasbarrini, A.(16);Kim, S.(17);Bae, Y.(17);Lee, S.(17);Lee, J.H.(17);Lee, J.(17);Lee, S.J.(18);Lee, S.G.(18);Kim, J.M.(18);
Created: Friday, 14 July 2023, 11:05 AM
P492: The UC Diet and Antibiotics for Treatment of Mild to Moderate Pediatric Ulcerative Colitis: A prospective open label pilot study
Year: 2021
Source: ECCO'21 Virtual
Authors: Sarbagili Shabat, C.(1,2);Albenberg, L.(3);Van Limbergen, J.(4,5);Otley, A.(6);Yaakov, M.(1);Wine, E.(7);Weiner, D.(1);Levine, A.(1,2);
Created: Wednesday, 2 June 2021, 4:12 PM
P493 Segmental colectomy vs. extended colectomy for colonic Crohn’s disease: results from 112 consecutive patients
Year: 2020
Source:

ECCO'20 Vienna

Authors:

A. Frontali1, A. Chierici1, X. Treton2, L. Maggiori1, Y. Bouhnik2, Y. Panis3

Created: Thursday, 30 January 2020, 10:12 AM
P493: Comparison of the efficacy of infliximab biosimilar (Remsima®) vs. infliximab original (Remicade®) in patients with inflammatory bowel disease
Year: 2018
Source: ECCO '18 Vienna
Authors:

M.F. Guerra Veloz1*, M. Belvis Jimenez1, T. Valdes Delgado1, R. Perea Amarillo1, L. Castro Laria1, B. Maldonado Pérez1, V. Merino2, A. Benítez Roldán1, A. Caunedo Álvarez1, F. Argüelles-Arias1

Created: Thursday, 21 February 2019, 9:14 AM
P493: Cost-effectiveness of venous thromboembolism prophylaxis after hospitalization in patients with Inflammatory Bowel Disease
Year: 2021
Source: ECCO'21 Virtual
Authors: Lee, K.(1);Lim, F.(2);Colombel, J.F.(3);Hur, C.(2);Faye, A.(3);
Created: Wednesday, 2 June 2021, 4:12 PM
P493: Efficacy of anti-TNF for internal fistula in Crohn's disease – results from a retrospective multicenter cohort study
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Kobayashi T.*1, Hishida A.2, Tanaka H.3, Bamba S.4, Yamada A.5, Toshimitsu F.6, Shinichiro S.7, Kamata N.8, Yoshino T.9, Hibi T.1 AIM Jr. Internal Fistula Study Group

Created: Wednesday, 20 February 2019, 10:36 AM
P493: Inflammatory sticturing Crohn’s diseases: results of medical treatment
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

N. Bellil1, N. Bibani1, M. Sabbah1, D. Trad1, H. Elloumi1, A. Ouakaa*1, D. Gargouri1

Created: Friday, 22 February 2019, 9:41 AM
P493: Prevalence and risk factors for postoperative septic complications in Crohn’s disease
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

M. Guasch1, 2, A. Clos1, M. Manyosa3, T. Lobatón3, J. R. Gómez2, M. Piñol4, E. Cabré3, J. Troya4, E. Domènech*3

Created: Friday, 22 February 2019, 9:49 AM
P493: QUASAR Induction Study 1 Cumulative Response to Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Peyrin-Biroulet, L.(1)*;Rubin, D.(2);Lichtenstein, G.(3);Shipitofsky, N.(4);Huang, K.H.(4);Germinaro, M.(4);Wilson, R.(5);Zhang, H.(5);DuVall, G.A.(6);Cao, Q.(7);Allegretti, J.(8);Feagan, B.(9);Hisamatsu, T.(10);Panés, J.(11);Dignass, A.(12);Bressler, B.(13);Sands, B.(14);
Created: Friday, 14 July 2023, 11:05 AM
P493: The synthetic glycan KB295 optimises microbiome composition and function in ulcerative colitis: Results from a proof of principle human study
Year: 2022
Source: ECCO'22
Authors: Meisner, J.(1);Miller , K.(1);Lee, J.(2);Jose, A.(2);Giuggio, M.(3);McComb , M.(1);Humphries, E.(3);Rosini, M.(4);Wingertzahn, M.(5);Shanahan, F.(6);E.T. van Hylckama Vlieg, J.(7);Dowling , M.(1);
Created: Friday, 11 February 2022, 3:56 PM
P494 The efficacy and safety of adalimumab for patients with moderately to severely active ulcerative colitis and predictors of response in Korea
Year: 2020
Source:

ECCO'20 Vienna

Authors:

S. Shin Shin1, S.J. Park2, Y. Kim1, J.P. Im3, H.J. Kim4, K.M. Lee5, J.W. Kim6, S.A. Jung7, J. Lee8, S.B. Kang9, S.J. Shin10, E.S. Kim11, Y.S. Kim12, T.O. Kim13, H.S. Kim14, D.I. Park15, H.K. Kim16, E.S. Kim17, Y.H. Kim18, D.H. Kim19, D. Teng20, J.H. Kim1, W.Y. Kim1, C.H. Choi1

Created: Thursday, 30 January 2020, 10:12 AM
P494: A serum metabolite panel predicts Crohn’s disease relapse in patients discontinuing infliximab and continuing antimetabolite therapy: sub-analysis of the SPARE Trial.
Year: 2022
Source: ECCO'22
Authors: Radford-Smith, D.(1);Satsangi, J.(2);Louis, E.(3);Laharie, D.(4);Ding, N.(5);Siegmund, B.(6);D'Haens, G.(7);Erik, H.(8);Yates, A.(9);Anthony, D.(1);Colombel, J.F.(10);Probert, F.(9);
Created: Friday, 11 February 2022, 3:56 PM
P494: Can Patients Monitor Response To Ustekinumab In The Real World?
Year: 2021
Source: ECCO'21 Virtual
Authors: Walsh, A.J.(1);Matini, L.(1);Kormilitzin, A.(2);Wilson, J.(1);Lyden, S.(1);Al-Hillawi, L.(1);Kantschuster, R.(1);White, L.(1);Payton, S.(1);Brain, O.(1);Palmer, R.(1);Ambrose, T.(1);Satsangi, J.(1);Travis, S.P.L.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P494: Impact of early optimization of ustekinumab on mid-term targets in severe Crohn's disease: THE MUST study
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Abdelmoula, A.(1)*;Chateau, T.(2);Hupe, M.(2);Boschetti, G.(3);Roblin, X.(4);Nancey, S.(3);Mathieu, N.(2);
Created: Friday, 14 July 2023, 11:05 AM
P494: Monocytic TNF production predicts response to infliximab treatment in Crohn’s disease but not ulcerative colitis
Year: 2018
Source: ECCO '18 Vienna
Authors:

B. Jessen1,2*, D. Lissner1, E. Sonnenberg1, M. Schumann1, F. Schmidt1, A. Kühl1, B. Siegmund1

Created: Thursday, 21 February 2019, 9:14 AM
P494: Multicentre cohort study to evaluate the need for re-intervention following multimodal treatment in Crohn's disease with perianal fistula
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Sebastian S.*1,2, Black C.2, Pugliese D.3, Armuzzi A.3, Sahnan K.4, Elkady S.M.4, Katsanos K.H.5, Christodoulou D.K.5, Selinger C.6, Maconi G.7, Fiorino G.8, Kopylov U.9, Davidov Y.9, Bosca-Watts M.M.10, Ellul P.11, Muscat M.11, Karmiris K.12, Fearnhead N.S.13, Allgar V.14, Hart A.L.4, Ben-Horin S.9, Danese S.8

Created: Wednesday, 20 February 2019, 10:36 AM
P494: Phenotypic analysis revealed features of disease severity in familial versus sporadic cases of inflammatory bowel disease
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

G. Maurizi, M. Giannotta*, V. Almerigogna, S. Biagini, A. Cozzi, G. Macrì, M. Milla

Created: Friday, 22 February 2019, 9:49 AM
P494: Regional survey on satisfaction with healthcare in inflammatory bowel disease patients
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

V. Borzan1,2, V. Orsic Fric*1,2, B. Borzan2

Created: Friday, 22 February 2019, 9:41 AM
P495 Usefulness of a capsule endoscopy scoring system in understanding the disease state of Crohn’s disease
Year: 2020
Source:

ECCO'20 Vienna

Authors:

T. Omori, H. Kambayashi, S. Murasugi, A. Ito, M. Yonezawa, K. Tokushige

Created: Thursday, 30 January 2020, 10:12 AM
P495: Biosimilar infliximab is effective and safe in inflammatory bowel disease patients naïve to anti-TNF therapy: a tertiary centre experience
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

M. Bortlik*1, 2, M. Kolar1, D. Duricova1, 3, K. Malickova4, V. Hruba1, N. Machkova1, K. Mitrova1, M. Lukas1, M. Lukas1, 4

Created: Friday, 22 February 2019, 9:49 AM